• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Taking advantage of a pitfall in glioma cancer stem cell epigenetics to develop novel therapies directed to cancer stem cells

Research Project

Project/Area Number 16K15640
Research Category

Grant-in-Aid for Challenging Exploratory Research

Allocation TypeMulti-year Fund
Research Field Neurosurgery
Research InstitutionYamagata University

Principal Investigator

KITANAKA Chifumi  山形大学, 医学部, 教授 (70260320)

Co-Investigator(Renkei-kenkyūsha) OKADA MASASHI  山形大学, 医学部, 講師 (70512614)
Project Period (FY) 2016-04-01 – 2018-03-31
Project Status Completed (Fiscal Year 2017)
Budget Amount *help
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2016: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Keywordsglioma-initiating cells / Tumor-initiating cells / Tumor-initiating cell / グリオーマ
Outline of Final Research Achievements

Cancer stem cells are a small subpopulation of immature, undifferentiated tumor cells characterized by therapy resistance as well as by their ability to initiate tumors on one hand and on the other to undergo differentiation into mature, non-cancer stem cells that no longer retain therapy resistance or tumor-initiating capacity. As such, cancer stem cells are deemed a major culprit of post-treatment tumor recurrence and therefore a key therapeutic target in the development of curative cancer therapies. Here in this research project, we tested our original working hypothesis that tri-methylation at H3K27 promotes the differentiation of glioma stem cells, an idea apparently paradoxical to what has been widely believed in the field of glioma stem cell research, in an attempt to develop novel therapies directed against glioma stem cells.

Report

(3 results)
  • 2017 Annual Research Report   Final Research Report ( PDF )
  • 2016 Research-status Report
  • Research Products

    (5 results)

All 2017 2016

All Journal Article (3 results) (of which Peer Reviewed: 3 results,  Open Access: 2 results,  Acknowledgement Compliant: 1 results) Presentation (2 results) (of which Invited: 2 results)

  • [Journal Article] Repositioning CEP-1347, a chemical agent originally developed for the treatment of Parkinson's disease, as an anti-cancer stem cell drug.2017

    • Author(s)
      Okada M, Takeda H, Sakaki H, Kuramoto K, Suzuki S, Sanomachi T, Togashi K, Seino S, Kitanaka C.
    • Journal Title

      Oncotarget.

      Volume: 8 Issue: 55 Pages: 94872-94882

    • DOI

      10.18632/oncotarget.22033

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Licochalcone A specifically induces cell death in glioma stem cells via mitochondrial dysfunction.2017

    • Author(s)
      Kuramoto K, Suzuki S, Sakaki H, Takeda H, Sanomachi T, Seino S, Narita Y, Kayama T, Kitanaka C, Okada M.
    • Journal Title

      FEBS Open Bio.

      Volume: 7 Issue: 6 Pages: 835-844

    • DOI

      10.1002/2211-5463.12226

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Impact of H3K27 Demethylase Inhibitor GSKJ4 on NSCLC Cells Alone and in Combination with Metformin.2016

    • Author(s)
      Watarai et al.
    • Journal Title

      Anticancer Research

      Volume: 36 Pages: 6083-6092

    • Related Report
      2016 Research-status Report
    • Peer Reviewed / Acknowledgement Compliant
  • [Presentation] グリオーマ幹細胞2017

    • Author(s)
      北中 千史
    • Organizer
      第37回日本脳神経外科学会コングレス総会
    • Related Report
      2017 Annual Research Report
    • Invited
  • [Presentation] 悪性グリオーマの新規治療戦略2017

    • Author(s)
      北中 千史
    • Organizer
      第76回日本癌学会学術総会
    • Related Report
      2017 Annual Research Report
    • Invited

URL: 

Published: 2016-04-21   Modified: 2019-03-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi